Compare BIII & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIII | CNTN |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | Hong Kong | United States |
| Employees | 3 | 12 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.2M | 185.3M |
| IPO Year | N/A | 2022 |
| Metric | BIII | CNTN |
|---|---|---|
| Price | $9.94 | $3.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.5K | ★ 751.3K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.83 | $2.14 |
| 52 Week High | $9.98 | $5.27 |
| Indicator | BIII | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 51.38 |
| Support Level | $9.83 | $3.04 |
| Resistance Level | $9.97 | $3.82 |
| Average True Range (ATR) | 0.01 | 0.34 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 60.00 | 60.60 |
Black Spade Acquisition III Co is a blank check company.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.